Abivax (NASDAQ:ABVX) Shares Down 3.4% Following Weak Earnings

Key Points

• Abivax shares fell 3.4% after the company reported a quarterly loss of $1.71 per share, missing the $0.92 consensus estimate, despite revenue of $1.37 million exceeding forecasts.
• The company plans to submit an obefazimod ulcerative-colitis drug application by the end of 2026. Abivax reported substantial cash resources and recent offering proceeds, extending its cash runway into the fourth quarter of 2029.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $156.69, though the company’s roughly $9 billion valuation depends heavily on obefazimod’s clinical and regulatory success.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) traded down 3.4% during trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $97.68 and last traded at $99.9150. 455,998 shares traded hands during trading, a decline of 68% from the average session volume of 1,419,077 shares. The stock had previously closed at $103.45.

The company reported ($1.71) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to the consensus estimate of $0.80 million.

Key Stories Impacting Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Abivax said it plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026. The company also reported €402.4 million in cash, cash equivalents and short-term investments at June 30, plus €767.1 million in net proceeds from its early-July offering, extending its cash runway into the fourth quarter of 2029. Abivax H1 Net Loss Widens; Plans Obefazimod NDA For Ulcerative Colitis By End Of 2026
• Positive Sentiment: The completed buyback of royalty certificates materially reduces a potential royalty overhang and leaves Abivax debt-free, improving financial flexibility ahead of possible commercialization. The company also appointed Tim Kelly as chief technical officer to support manufacturing, quality and commercial-supply readiness. Abivax Presents Business Updates and First Half 2026 Financial Results
• Neutral Sentiment: Analysts maintain an average “Moderate Buy” rating, suggesting that Wall Street remains constructive on the company’s longer-term prospects, although the stock’s roughly $9 billion valuation depends heavily on the success and regulatory progress of obefazimod. Abivax Receives Average Rating of Moderate Buy
• Neutral Sentiment: Chris Rabbat will succeed Fabio Cataldi as chief medical officer. The leadership transition may support continued clinical and regulatory execution, but it also introduces an additional management change as Abivax approaches key development milestones. Abivax Announces Chief Medical Officer Succession
• Negative Sentiment: Abivax reported a quarterly loss of $1.71 per share, substantially worse than the $0.92 consensus estimate. Although quarterly revenue of $1.37 million exceeded the $0.80 million forecast, the wider-than-expected loss and continued clinical-stage cash burn are weighing on sentiment. Abivax Releases Earnings Results and Misses EPS Expectations

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group raised shares of Abivax from a "hold" rating to a "buy" rating and lifted their target price for the stock from $108.00 to $158.00 in a research note on Tuesday, June 30th. Wedbush lowered their price objective on Abivax from $140.00 to $118.00 and set a "neutral" rating for the company in a research report on Tuesday. Morgan Stanley reissued an "overweight" rating and issued a $180.00 price objective on shares of Abivax in a research note on Friday, July 24th. The Goldman Sachs Group began coverage on Abivax in a research note on Wednesday, September 9th. They set a "buy" rating and a $155.00 target price for the company. Finally, Leerink Partners boosted their price target on Abivax from $140.00 to $148.00 and gave the company an "outperform" rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $156.69.

Institutional Investors Weigh In On Abivax

A number of hedge funds have recently added to or reduced their stakes in ABVX. Versant Capital Management Inc acquired a new position in shares of Abivax during the second quarter worth approximately $30,000. GHP Investment Advisors Inc. increased its stake in Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company's stock valued at $26,000 after purchasing an additional 140 shares in the last quarter. Assetmark Inc. increased its stake in Abivax by 41.5% during the 1st quarter. Assetmark Inc. now owns 886 shares of the company's stock valued at $99,000 after purchasing an additional 260 shares in the last quarter. Troluce Capital Advisors LLC acquired a new position in Abivax during the second quarter worth $133,000. Finally, Clearstead Advisors LLC bought a new position in shares of Abivax in the fourth quarter valued at $138,000. Institutional investors and hedge funds own 47.91% of the company's stock.

Abivax Stock Down 5.1%

The stock has a market capitalization of $8.58 billion, a P/E ratio of -18.86 and a beta of 0.96. The business's 50 day simple moving average is $120.76 and its two-hundred day simple moving average is $117.67.

Abivax Company Profile

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.